Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 6:6:1265846.
doi: 10.3389/fdgth.2024.1265846. eCollection 2024.

Multidimensional digital biomarker phenotypes for mild cognitive impairment: considerations for early identification, diagnosis and monitoring

Tracy Milner  1 , Matthew R G Brown  2   3 , Chelsea Jones  1   3 , Ada W S Leung  1   4   5 , Suzette Brémault-Phillips  1   3   4
Affiliations

Multidimensional digital biomarker phenotypes for mild cognitive impairment: considerations for early identification, diagnosis and monitoring

Tracy Milner et al. Front Digit Health. .

Abstract

Mild Cognitive Impairment (MCI) poses a challenge for a growing population worldwide. Early identification of risk for and diagnosis of MCI is critical to providing the right interventions at the right time. The paucity of reliable, valid, and scalable methods for predicting, diagnosing, and monitoring MCI with traditional biomarkers is noteworthy. Digital biomarkers hold new promise in understanding MCI. Identifying digital biomarkers specifically for MCI, however, is complex. The biomarker profile for MCI is expected to be multidimensional with multiple phenotypes based on different etiologies. Advanced methodological approaches, such as high-dimensional statistics and deep machine learning, will be needed to build these multidimensional digital biomarker profiles for MCI. Comparing patients to these MCI phenotypes in clinical practice can assist clinicians in better determining etiologies, some of which may be reversible, and developing more precise care plans. Key considerations in developing reliable multidimensional digital biomarker profiles specific to an MCI population are also explored.

Keywords: MCI; biomarkers; clinical; cognitive; digital; machine learning; phenotypes.

PubMed Disclaimer

Conflict of interest statement

TM has a small, minority share interest in a public company, Highmark Interactive, that delivers digital technology and services for brain and mental health. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Tang F, Uchendu I, Wang F, Dodge HH, Zhou J. Scalable diagnostic screening of mild cognitive impairment using AI dialogue agent. Sci Rep. (2020) 10(1):1–11. 10.1038/s41598-020-61994-0 - DOI - PMC - PubMed
    1. Chehrehnegar N, Nejati V, Shati M, Rashedi V, Lotfi M, Adelirad F, et al. Early detection of cognitive disturbances in mild cognitive impairment: a systematic review of observational studies. Psychogeriatrics. (2020) 20(2):212–28. 10.1111/psyg.12484 - DOI - PubMed
    1. Sanford AM. Mild cognitive impairment. Clin Geriatr Med. (2017) 33(3):325–37. 10.1016/j.cger.2017.02.005 - DOI - PubMed
    1. Cavedoni S, Chirico A, Pedroli E, Cipresso P, Riva G. Digital biomarkers for the early detection of mild cognitive impairment: artificial intelligence meets virtual reality. Front Hum Neurosci. (2020) 14:245. 10.3389/fnhum.2020.00245 - DOI - PMC - PubMed
    1. 2018 Alzheimer’s disease facts and figures Includes a Special report on the financial and personal benefits of early diagnosis. Available online at: https://www.alz.org/media/HomeOffice/Facts%20and%20Figures/facts-and-fig... (accessed April 19, 2022).

LinkOut - more resources